Involving Oxidoreductase Patents (Class 435/25)
-
Patent number: 8252559Abstract: A method and system for selectively fluorinating organic molecules on a target site wherein the target site is activated and then fluorinated are shown together with a method and system for identifying a molecule having a biological activity.Type: GrantFiled: February 4, 2009Date of Patent: August 28, 2012Assignee: The California Institute of TechnologyInventors: Rudi Fasan, Frances H. Arnold
-
Publication number: 20120216304Abstract: Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided.Type: ApplicationFiled: October 6, 2011Publication date: August 23, 2012Inventors: Sangeeta N. BHATIA, Alice A. CHEN, Shengyong Ng
-
Publication number: 20120208226Abstract: In one form, a mutant fructosyl amino acid oxidase modified at an amino acid residue involved in a proton relay system is provided. The mutant fructosyl amino acid oxidase has reduced oxidase activity while substantially maintaining its dehydrogenase activity. Other forms include an assay device and assay method for measuring glycated protein. Still, other forms include unique methods, techniques, systems and devices involving a mutant fructosyl amino acid oxidase.Type: ApplicationFiled: February 3, 2012Publication date: August 16, 2012Inventors: Kazunori Ikebukuro, Sode Koji
-
Patent number: 8241845Abstract: The invention provides an isolated, novel steroid 5?-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.Type: GrantFiled: March 16, 2009Date of Patent: August 14, 2012Assignee: Health Research Inc.Inventors: James L. Mohler, Mark Titus, Olga Kozyreva, O. Harris Ford, III, Elsbieta Kawinski, Yun Li
-
Publication number: 20120202235Abstract: In one form, a fructosyl peptidyl oxidase derived from a budding yeast Phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying HbA1c with higher sensitivity and specificity. Still, other forms include unique methods, techniques, systems and devices involving a fructosyl peptidyl oxidase.Type: ApplicationFiled: February 3, 2012Publication date: August 9, 2012Inventors: Kazunori Ikebukuro, Sode Koji
-
Patent number: 8236153Abstract: An immobilization carrier containing an electron acceptor compound is used in addition to glutaraldehyde and poly-L-lysine to immobilize an enzyme and an electron acceptor compound simultaneously to an electrode. For example, here are used diaphorase as the enzyme and 2-amino-3-carboxy-1, 4-naphthoquinone (ACNQ) as the electron acceptor compound.Type: GrantFiled: February 27, 2009Date of Patent: August 7, 2012Assignee: Sony CorporationInventors: Atsushi Sato, Tokuji Ikeda, Kenji Kano
-
Patent number: 8232047Abstract: Reagents and compositions for use in reactions catalysed by luciferase enzymes, and in particular for use in luciferase-based gene reporter assays are described. The invention also provides methods and compositions for, inter alia, increasing the sensitivity and/or improving the kinetics of luciferase-catalysed reactions.Type: GrantFiled: October 24, 2007Date of Patent: July 31, 2012Assignee: Gene Stream Pty Ltd.Inventors: Marco Peter Leu, John Michael Daly
-
Publication number: 20120190054Abstract: Enzymes and/or polypeptides and/or mixtures of interest are evaluated during hydrolysis of cellulosic material by the use of indicator constituents such as fluorescent agents, resulting in efficient high-throughput analysis of enzymes and/or polypeptides. A high-throughput assay for the analysis of inter alia, pretreated corn stover (PCS) hydrolysis is also disclosed.Type: ApplicationFiled: July 13, 2010Publication date: July 26, 2012Applicant: NOVOZYMES A/SInventors: Marco Malten, Keith McFarland
-
Patent number: 8227206Abstract: The present invention disclosed a method to detect pregnancy and identify pseudopregnancy, pregnancy and pregnancy loss using ceruloplasmin as a non-invasive marker in animal urine samples. More specifically, this invention provide provides a method to use a non-invasive marker of inflammation, the acute phase protein ceruloplasmin, in urine samples to detect pregnancy and to distinguish between pregnancy and pseudopregnancy in mammals. The steps of this method include: collecting fresh urine sample from a mammal, adding a ceruloplasmin substrate to the urine sample, measuring oxidase activity of said ceruloplasmin through a sequential reading of absorbance of a photometric product using a spectrophotometer to determine the concentration of ceruloplasmin in the at least one urine sample.Type: GrantFiled: March 23, 2012Date of Patent: July 24, 2012Assignee: Memphis Zoo, Inc.Inventor: Erin Lynn Willis
-
Patent number: 8216811Abstract: Described herein are novel nucleic acids, proteins and methods that can be used to provide new catalysts with desirable traits for industrial processes. In particular, novel reductases isolated from the environment using PCR methods are described.Type: GrantFiled: March 4, 2011Date of Patent: July 10, 2012Assignee: Danisco US Inc.Inventors: Mark Donnelly, William H. Eschenfeldt, Jonathan Trent
-
Patent number: 8216815Abstract: The disclosure relates to methods of producing fatty alcohols from recombinant host cells comprising genes encoding heterologous fatty acyl-CoA reductase (FAR) enzymes. The disclosure further relates to FAR enzymes and functional fragments thereof derived from marine bacterium and particularly marine gamma proteobacterium such as Marinobacter and Oceanobacter; polynucleotides encoding the FAR enzymes and vectors and host cells comprising the same.Type: GrantFiled: June 29, 2010Date of Patent: July 10, 2012Assignee: Codexis, Inc.Inventors: Robert McDaniel, Behnaz Behrouzian, Louis Clark, Douglas Hattendorf, Fernando Valle
-
Publication number: 20120171693Abstract: The disclosure provides methods for identifying and producing stabilized chimeric proteins.Type: ApplicationFiled: January 5, 2008Publication date: July 5, 2012Applicant: THE CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Frances H. Arnold, Yougen Li
-
Patent number: 8211662Abstract: The present invention relates to an enzyme substrate for detecting nitroreductase activity of formula (I) below: in which X is S, NX1, O or NX1-CO; R1 is nothing or a substituent selected from Cl, CH3, Br, F, I, alkyl, aryl and carboxyl; R2 is nothing or a substituent selected from Cl, O—CH2—O, O—CH3, F, diethylenediamine-CH3, NR3R4, Br, I, alkyl, aryl, carboxyl, NO2 and R3 and R4 are independently H or an alkyl group containing from 1 to 4 carbon atoms; and X1 is selected from H, CH3, C2H4Ph, OH, alkyl and aryl.Type: GrantFiled: May 29, 2008Date of Patent: July 3, 2012Assignee: BiomerieuxInventors: Olivier Fabrega, Arthur James, Vindhya Lakshika Salwatura, Sylvain Orenga, Stephen Stanforth
-
Publication number: 20120164674Abstract: Herein are disclosed compositions, washes, rinses, devices, systems and methods for biomarker stabilization, in part in bodily fluids, as well as methods and formulations for improving the sampling and testing of fluids for biomarkers.Type: ApplicationFiled: October 27, 2011Publication date: June 28, 2012Inventors: Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
-
Publication number: 20120165328Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.Type: ApplicationFiled: February 24, 2012Publication date: June 28, 2012Applicant: Pharmacyclics, Inc.Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
-
Publication number: 20120164154Abstract: It is disclosed here that insulin sensitivity in a human or non-human animal can be increased by reducing stearoyl-CoA desaturase-1 (SCD1) activity in the animal. This provides a new tool for treating and preventing type 2 diabetes. Also disclosed are methods for identifying agents that can increase insulin sensitivity in a human or non-human animal through determining the agents' effects on SCD1 activity.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Inventors: James M. Ntambi, Alan D. Attie, Makoto Miyazaki
-
Patent number: 8206311Abstract: A high-sensitivity analyzer for nitric oxide in exhaled breath at levels of 200 ppb or less with a sensor containing cytochrome C is rendered capable of multiple uses without the need for installing a new sensor for each use. This capability is achieved by regenerating the analyzer after each use by purging the sensor and surrounding regions with NOx-free air in a controlled manner, preferably in pulses separated by equilibration periods.Type: GrantFiled: April 1, 2009Date of Patent: June 26, 2012Assignee: Aerocrine ABInventors: David J. Chazan, Bhairavi R. Parikh, Bryan P. Flaherty, David J. Anvar, Brian A. Awabdy
-
Publication number: 20120149581Abstract: Preparation of oxidation-reduction (redox) nano-medicine quantum dot room temperature superconductor quantum bit (qubit) networks includes processes of making unitary, binary, ternary, and/or quaternary liquid pharmaceutical ingredients of an antioxidase antioxidant, a ?-adrenergic receptor agonist, a P2-purinergic receptor agonist, and/or a phenylalkylamine calcium channel blocker in combination with either 1:20 xanthine oxidase (XO):xanthine (X) or X alone in a liquid phase by using the L16(2)15 and L9(3)4 orthogonal optimization design protocols and modulating spatial distance constraint from about 0.1 ? to about 200 ? as well as a 10 class clean bottom-up self-assembly approach.Type: ApplicationFiled: December 19, 2007Publication date: June 14, 2012Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventor: Yan Fang
-
Publication number: 20120149576Abstract: The present invention enables providing a method for cultivating a crop plant into which has been introduced either one or both of (1) DNA comprising a nucleotide sequence encoding the amino acid sequence of a cytochrome P450 that shows saflufenacil metabolizing activity and (2) DNA comprising a nucleotide sequence encoding the amino acid sequence of a protein that shows protoporphyrinogen IX oxidase activity, wherein said method comprises applying a weed control agent that contains saflufenacil as an active ingredient to an area where said crop plant is cultivated; among others.Type: ApplicationFiled: June 9, 2010Publication date: June 14, 2012Inventors: Takanori Saijo, Akitsu Nagasawa
-
Publication number: 20120148657Abstract: In general, the present invention relates to epidermal lipoxygenase obtained from axolotl and pharmaceutical compositions containing the same. In particular, in a first aspect the present invention relates to pharmaceutical compositions containing lipoxygenase obtained from axolotl or functional homologues thereof having a lipoxygenase activity, in particular for use in wound healing, bone healing or conditioning of injured tissue, e.g. in wound dressings. In a further aspect, the present inventions relates to cosmetical compositions containing said lipoxygenase. Finally, the present invention provides methods for identifying modulators of wound healing, scarring, etc. comprising the step of determining compounds able to alterate the lipoxygenase enzyme activity.Type: ApplicationFiled: May 28, 2010Publication date: June 14, 2012Inventors: Kerstin Reimers-Fadhlaoui, Peter Vogt, Menger Björn
-
Publication number: 20120142041Abstract: Compositions and methods for the measuring toxicity, antioxidant capacity, and oxidative stress are provided.Type: ApplicationFiled: May 14, 2010Publication date: June 7, 2012Inventor: Iraimoudi S. Ayene
-
Publication number: 20120141998Abstract: The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.Type: ApplicationFiled: February 15, 2012Publication date: June 7, 2012Applicant: GEORGIA HEALTH SCIENCES UNIVERSITYInventors: ANDREW L. MELLOR, DAVID H. MUNN, JEFFREY ROBERTS LEE
-
Publication number: 20120142040Abstract: The invention provides methods and kits for characterizing the activity of a methyltransferase or demethylase. The method involves enzymatically methylating or demethylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically methylating the peptide substrate with methyl groups that differ in molecular weight from the enzymatically added or removed methyl groups. Typically, deuterated or 13C formaldehyde is used to non-enzymatically methylate the substrate. The fully methylated substrate is then characterized by mass spectrometry to determine the ratio of enzymatically produced nonmethyl, monomethyl, and dimethyl residues on the peptide.Type: ApplicationFiled: December 4, 2010Publication date: June 7, 2012Inventors: Alan J. Tackett, Nathan L. Avaritt, Lauren P. Blair
-
Publication number: 20120142615Abstract: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.Type: ApplicationFiled: December 13, 2011Publication date: June 7, 2012Applicants: Human ServiceInventors: Jau-Shyong Hong, Liya Qin, Guorong Li, Michelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng
-
Patent number: 8187851Abstract: A method for formulating and immobilizing a protein and a protein matrix formed by the method. The protein matrix preparation method results in a physically and chemically stable protein matrix that has low swelling, non-leaching, high activity, and high mechanical strength properties. The method includes cross-linking and hardening the protein mixture and using a mold to form a protein into a desired shape and size.Type: GrantFiled: July 24, 2008Date of Patent: May 29, 2012Assignee: Medtronic Minimed, Inc.Inventors: Rajiv Shah, Bahar Reghabi, Rudy Montalvo, Yanan Zhang
-
Publication number: 20120129205Abstract: The invention relates to the use of a compound having formula (I) as an enzymatic substrate for the detection of a nitroreductase activity or as an enzymatic substrate for the detection of a nitroreductase activity and indicator of pH, wherein: W1, W2, W3 and W4 are independently H, Br, Cl, F, I, alkyl, alkoxy, thiomethyl, perfluoroalkyl, nitro, cyano, carboxyl (including the esters or amides thereof) or any combination of same; n=0, 1 or 2; U and V are N, N+R, CZ4, R being H, alkyl, aralkyl, aryl, alkanoic or alkylsulphonic, preferably if U is CZ4, V is N or N+R and, if V is CZ4, U is N or N+R; and Z1, Z2, Z3 and Z4 are independently H, Br, Cl, F, I, alkyl, aryl, alkoxy, perfluoroalkyl, nitro, cyano, carboxyl, sulphonyl, including the sulphonyl or carboxyl amides or esters thereof, and the salts of same.Type: ApplicationFiled: July 29, 2010Publication date: May 24, 2012Applicant: bioMerieuxInventors: Arthur James, Sylvain Orenga, John Perry, Vindhya Salwatura, Stephen Stanforth
-
Publication number: 20120129202Abstract: Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) stabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the effects of glycated hemoglobin, and an assay method are provided. Thus, the contents of a glycated protein and glycated albumin can be more accurately determined.Type: ApplicationFiled: December 9, 2011Publication date: May 24, 2012Inventors: Takuji Kouzuma, Issei Yoshioka, Motoo Arai, Junichi Sumitani, Shigeyuki Imamura
-
Publication number: 20120129204Abstract: The invention relates to the use of a compound having formula (I) as an enzymatic substrate for the detection of a nitroreductase activity, wherein: W1, W2, W3 and W4 are independently H, Br, Cl, F, I, alkyl, alkoxy, thiomethyl, perfluoroalkyl, nitro, cyano, carboxyl (including the esters or amides thereof) or any combination of same; n=0, 1 or 2; U is N or N+R and V is CZ6 N or N+R or V is N or N+R and U is CZ6, R being H, alkyl, aralkyl, aryl, alkanoic or alkylsulphonic; and Z1, Z2, Z3, Z4, Z5 and Z6 are independently H, Br, Cl, F, I, alkyl, aryl, alkoxy, perfluoroalkyl, nitro, cyano, carboxyl, sulphonyl, including the sulphonyl or carboxyl amides or esters thereof, and the salts of same.Type: ApplicationFiled: July 29, 2010Publication date: May 24, 2012Applicant: bioMerieux, SAInventors: Olivier Fabrega, Arthur James, Sylvain Orenga, John Perry, Vindhya Salwatura, Stephen Stanforth
-
Publication number: 20120121554Abstract: The present invention is directed, among other things, to using secondary metabolites in the mevalonate pathway (such as, for example, HMG) and/or structurally related compounds to mediate biological activities (e.g., for therapeutic applications) and/or as diagnostic agents. In some embodiments, the biological activities comprise one or more pleiotropic effects of statins (such as, for example, angiogenesis, promoting vascular function, anti-inflammatory action, immunomodulation, etc.). Also provided are methods of screening for mevalonate pathway secondary metabolites, methods of producing HMG, and methods of diagnosing comprising measuring amount of mevalonate pathway secondary metabolites.Type: ApplicationFiled: April 30, 2010Publication date: May 17, 2012Applicant: EDENSPACE SYSTEMS CORPORATIONInventor: Kirk Pappan
-
Publication number: 20120121568Abstract: The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.Type: ApplicationFiled: September 20, 2011Publication date: May 17, 2012Inventors: Danica Chen, Xiaolei Qiu
-
Publication number: 20120122131Abstract: Provided are methods for detecting a metabolic disorder in an individual using mass spectrometry. One method involves (a) contacting a sample containing (i) a metabolically indicative enzyme and (ii) a metabolic analyte, with a substrate for the enzyme to produce a reaction admixture, under conditions wherein the enzyme is capable of acting on a corresponding substrate to generate a product, and wherein a protease inhibitor is present; (b) contacting the reaction admixture with a reagent that inhibits the ability of the enzyme to act on a corresponding substrate, wherein the metabolic analyte and the product are soluble in the reagent; to produce a test sample and (c) determining the presence or amount of the metabolic analyte and the product contained in the test sample using mass spectrometry, wherein a determined presence or amount of the metabolic analyte and the product correlates with presence or absence of the metabolic disorder.Type: ApplicationFiled: January 24, 2012Publication date: May 17, 2012Applicant: PerkinElmer Health Sciences, Inc.Inventor: Blas Cerda
-
Publication number: 20120122136Abstract: Provided is a compound comprising the structure: (SIG)-(SI-MOD)m. In this compound, SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. With this compound, when MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided is a method of determining whether a sample comprises an activator, using the above-described compound. Additionally provided is a method of determining whether a cell comprises a nitroreductase using the above-described compound where nitroreductase is the activator. Further provided is a method of determining whether a mammalian cell is hypoxic using the above-described compound where nitroreductase is the activator.Type: ApplicationFiled: November 16, 2010Publication date: May 17, 2012Applicant: ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC.Inventors: Maciej Szczepanik, Irina V. Lebedeva, Yuejun Xiang, Praveen Pande, Wayne Forrest Patton
-
Publication number: 20120122137Abstract: The invention relates to the use of a compound having formula (I) as an enzymatic substrate for the detection of a nitroreductase activity, wherein: W1, W2, W3 and W4 are independently H, Br, Cl, F, I, alkyl, alkoxy, thiomethyl, perfluoroalkyl, nitro, cyano, carboxyl (including the esters or amides thereof) or any combination of same; n=0, 1 or 2; X is NR, CZ5Z6, S or O, R being H, alkyl, aralkyl, aryl, alkanoic or alkylsulphonie, Z5 and Z6 being an alkyl; Y is N or N+R, R being alkyl, aralkyl, aryl, alkanoic or alkylsulphonic; Z1, Z2, Z3 and Z4 are independently H, Br, Cl, F, I, alkyl, aryl, alkoxy, perfluoroalkyl, nitro, cyano, carboxyl, sulphonyl, including the sulphonyl or carboxyl amides or esters thereof, and the salts of same.Type: ApplicationFiled: July 29, 2010Publication date: May 17, 2012Applicant: bioMérieux S.A.Inventors: Olivier Fabrega, Arthur James, Sylvain Orenga, John Perry, Vindhya Salwatura, Stephen Stanforth
-
Publication number: 20120114605Abstract: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.Type: ApplicationFiled: April 26, 2010Publication date: May 10, 2012Inventor: Shaoguang Li
-
Patent number: 8173386Abstract: Methods of assaying enzyme-mediated oxidative demethylation are provided according to embodiments of the present invention which includes combining, under reaction conditions, an oxidative demethylation enzyme, a substrate for the oxidative demethylation enzyme and a formaldehyde detection reagent. Detection of fluorescence is indicative of formaldehyde generated by oxidative demethylation of the substrate by the enzyme, the fluorescence resulting from reaction of formaldehyde and the formaldehyde detection reagent.Type: GrantFiled: January 14, 2009Date of Patent: May 8, 2012Assignee: Arbor Assays, LLCInventors: Russell Hart, Barbara Scheuer, Raymond Trievel
-
Patent number: 8173402Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.Type: GrantFiled: January 14, 2011Date of Patent: May 8, 2012Assignee: Aventis Pharma S.A.Inventors: Bruno Dumas, Gilles Cauet, Eric Degryse, Tilman Achstetter
-
Publication number: 20120107265Abstract: In various embodiments, the present disclosure provides a method and enzyme for forming various compounds, such as monoterpenes and monoterpenoid compounds. In a specific example, the present disclosure provides a method for producing one or more of (?)-ipsdienol, (?)-ipsenol, ipsenone, and ipsdienone. The present disclosure also provides methods of using compounds formed from the disclosed method and enzyme.Type: ApplicationFiled: November 17, 2009Publication date: May 3, 2012Inventors: Claus Tittiger, Rubi Figueroa-Teran, Gary J. Blomquist
-
Publication number: 20120100566Abstract: Chemiluminescent compositions, methods, assays and kits for oxidative enzymes are described. Further disclosed are dioxetane compounds of the form: 0-0 ?R R R T (i) where R can independently be any branched alkyl or cycloalkyl group which provides stabilization for the dioxetane or where both R groups together form a cycloalkyl or polycycloalkyl moiety spiro bound to the dioxetane ring, wherein each R group or the spiro bound moiety can be unsubstituted or substituted with one or more electron-withdrawing groups or electron donating groups, or groups providing preferential oxidative isozyme substrate recognition, and wherein Ri is an aryl group, or an alkyl group of 1-20 carbon atoms, which can be optionally substituted with 1 or more halogen atoms, and wherein T is an aryl or heteroaryl ring capable of emitting light upon enzyme activated decomposition of the dioxetane I. Kits, methods and assays are also disclosed that comprise the dioxetane compounds.Type: ApplicationFiled: March 1, 2010Publication date: April 26, 2012
-
Publication number: 20120100567Abstract: A method for measuring a target object in a sample by using an oxidase, wherein the influence of dissolved oxygen in the sample can be corrected, is provided. The method comprises: obtaining measurement values by causing the target object in the sample to react with the oxidase under different conditions of two or more types; and performing a correction based on the obtained two or more measurement values and a correction method preliminarily set so as to correct the influence of dissolved oxygen in the sample.Type: ApplicationFiled: October 20, 2011Publication date: April 26, 2012Applicant: ARKRAY, Inc.Inventor: Hisashi Kaneda
-
Patent number: 8163499Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: GrantFiled: July 28, 2009Date of Patent: April 24, 2012Assignee: Prometheus Laboratories Inc.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Patent number: 8163880Abstract: A fusion protein that is expressed in a recombinant protein body-like assembly (RPBLA) in host eukaryotic cells and organisms is disclosed. More particularly, a biologically active polypeptide fused to a protein sequence that mediates the induction of RPBLA formation is expressed and accumulated in host cells after transformation with an appropriate vector. The eukaryotic host cell does not produce protein bodies in the absence of the fusion protein. Methods for preparing and using the RPBLAs and the fusion protein are also disclosed, as are nucleic acid molecules that encode the fusion proteins.Type: GrantFiled: February 22, 2007Date of Patent: April 24, 2012Assignee: ERA Biotech S.A.Inventors: Peter Bernard Heifetz, Blanca Llompart Royo, Pablo Marzábal Luna, Miriam Bastida Virgili, Ma Dolores Ludevid Múgica, Margarita Torrent Quetglas, Kevin James O'Connor, Roser Pallisse Bergwerf, Ma Immaculada Ilop Tous
-
Publication number: 20120090044Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: ApplicationFiled: November 4, 2011Publication date: April 12, 2012Inventors: George C. Prendergast, Richard Metz
-
Patent number: 8153392Abstract: A method of detecting, diagnosing and prognosticating atherosclerosis by measuring the activities of ?6 and ?5 desaturases is described. It is suggested that enhancing the activities of ?6 and ?5 desaturases results in an increase in the plasma, leukocyte, platelet and endothelial cell levels of ?-linolenic, dihomo-?-linolenic, arachidonic, stearidonic, 20:4 ?-3, eicosapentaneoic and docosahexaenoic acids and PGE1 (prostaglandin E1), prostacyclin (PGI2), prostaglandin I3 (PGI3), lipoxins, resolvins, protectins, nitric oxide, and nitrolipids that prevent, arrest and reverse atherosclerosis. The invention is also directed to the delivery of proteins, peptides, lipids, lipoproteins, glycolipids, statins and troglitazones and their derivatives, and other compounds (synthetic or natural), cDNA clones and genes of ?6 and ?5 desaturases to enhance the activities of ?6 and ?5 desaturases in vivo to prevent, arrest, reverse and treat atherosclerosis.Type: GrantFiled: March 28, 2008Date of Patent: April 10, 2012Inventors: Appa Rao Allam, Undurti Narasimha Das
-
Publication number: 20120082983Abstract: Compositions and methods are provided that relate to the bioremediation of chlorinated ethenes, particularly the bioremediation of vinyl chloride by Dehalococcoides-like organisms. An isolated strain of bacteria, Dehalococcoides sp. strain VS, that metabolizes vinyl chloride is provided; the genetic sequence of the enzyme responsible for vinyl chloride dehalogenation; methods of assessing the capability of endogenous organisms at an environmental site to metabolize vinyl chloride; and a method of using the strains of the invention for bioremediation.Type: ApplicationFiled: November 11, 2011Publication date: April 5, 2012Inventors: Alfred M. Spormann, Jochen A. Muller, Bettina M. Rosner, Gregory Von Abendroth, Galit Meshulam-Simon, Perry L. McCarty
-
Publication number: 20120083426Abstract: A method is described for releasing a soluble or membrane associated intracellular protein of interest (POI) comprising the steps of: providing a cell comprising a soluble or membrane associated intracellular POI; contacting the cell with a membrane extracting composition; and causing the POI to be released from the cell under conditions sufficient for the specific release of the POI and in a soluble form.Type: ApplicationFiled: July 21, 2011Publication date: April 5, 2012Inventors: Claus Lindvald JOHANSEN, Soren Kjaerulff, Susan Mampusta Madrid, Henrik Pedersen, Charlotte Horsmans Poulsen, Masoud Rajabi Zargahi
-
Patent number: 8148100Abstract: The present invention comprises a method for assaying oxygenase activity the method comprising monitoring oxygenase activity of Mina53.Type: GrantFiled: September 25, 2006Date of Patent: April 3, 2012Assignee: ISIS Innovation LimitedInventors: Christopher Joseph Schofield, Michael Arnold McDonough, Nicolas Joseph Jean Granatino
-
Publication number: 20120076815Abstract: This invention provides identification and characterization of racemases and definition of protein signatures of these racemases. This invention also provides identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs. Antibodies specific for the peptides and to immune complexes of these antibodies with the peptides are also provided. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides.Type: ApplicationFiled: September 30, 2010Publication date: March 29, 2012Inventors: Paola Minoprio, Nathalie Chamond, Wim M. Degrave, Armand Berneman
-
Patent number: 8137927Abstract: A method for formulating and immobilizing a protein and a protein matrix formed by the method. The protein matrix preparation method results in a physically and chemically stable protein matrix that has low swelling, non-leaching, high activity, and high mechanical strength properties. The method includes cross-linking and hardening the protein mixture and using a mold to form a protein into a desired shape and size.Type: GrantFiled: May 4, 2005Date of Patent: March 20, 2012Assignee: Medtronic MiniMed, Inc.Inventors: Rajiv Shah, Bahar Reghabi, Rudy Montalvo, Yanan Zhang
-
Publication number: 20120064559Abstract: According to one embodiment, a test element includes a base, a pair of optical element units, an optical waveguide unit, a detection unit and a holding unit. The base has transparency. The pair of optical element units are arranged away from each other on a major surface of the base. The optical waveguide unit is provided on the major surface of the base. The detection unit is provided on a major surface of the optical waveguide unit of between the optical element units. The major surface of the optical waveguide unit is an opposite side which touches the base. The holding unit is in a frame shape, and one end of the holding unit being is provided to protrude from a major surface of the detection unit. The detection unit includes a color former and a film-formed body holding the color former.Type: ApplicationFiled: August 11, 2011Publication date: March 15, 2012Applicant: Kabushiki Kaisha ToshibaInventors: Ichiro TONO, Takaaki Wada, Kayoko Oomiya, Shingo Kasai, Masaaki Hirakawa
-
Patent number: RE43497Abstract: The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.Type: GrantFiled: November 2, 2000Date of Patent: June 26, 2012Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.Inventors: Herwig Brunner, Jürgen Bernhagen, Robert Kleemann, Ralf Mischke, Afroditi Kapurniotu